Preclinical and clinical studies suggest that enzyme replacement therapy with recombinant human ADAMTS13 protein (rhADAMTS13) is effective and safe in treatment of TTP. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.